Northstrive Biosciences Announces Completion of Phase II of AI Development Program with YuvaBio Using MitoNova™ Artificial Intelligence (AI) Platform to Develop Therapies for Obesity and Cardiometabolic Diseases
Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has completed Phase II of its AI Development Program with Yuva Biosciences. The collaboration leverages YuvaBio's proprietary MitoNova™ AI platform to discover potential treatments for obesity and cardiometabolic diseases.
During Phase II, YuvaBio analyzed 12 curated libraries of compounds focused on obesity, cardiometabolic disorders, and lipid & glucose metabolism. The AI platform screened these compounds to evaluate their predicted impact on muscle preservation and metabolic health. YuvaBio has now delivered a shortlist of small molecule candidates to Northstrive for biological validation and potential clinical development.
Northstrive Biosciences, controllata di PMGC Holdings (NASDAQ: ELAB), ha completato la Fase II del suo Programma di Sviluppo basato sull'IA insieme a Yuva Biosciences. La collaborazione sfrutta la piattaforma proprietaria MitoNova™ AI di YuvaBio per identificare potenziali terapie per l'obesità e le malattie cardiometaboliche.
Durante la Fase II, YuvaBio ha analizzato 12 librerie selezionate di composti focalizzati su obesità, disturbi cardiometabolici e metabolismo dei lipidi e del glucosio. La piattaforma AI ha esaminato questi composti per valutarne l'impatto previsto sulla conservazione della massa muscolare e sulla salute metabolica. YuvaBio ha ora consegnato a Northstrive una short list di candidati a piccole molecole per la validazione biologica e il possibile sviluppo clinico.
Northstrive Biosciences, subsidiaria de PMGC Holdings (NASDAQ: ELAB), ha completado la Fase II de su Programa de Desarrollo con IA junto a Yuva Biosciences. La colaboración aprovecha la plataforma propietaria MitoNova™ AI de YuvaBio para descubrir posibles tratamientos contra la obesidad y las enfermedades cardiometabólicas.
Durante la Fase II, YuvaBio analizó 12 bibliotecas seleccionadas de compuestos centradas en obesidad, trastornos cardiometabólicos y el metabolismo de lípidos y glucosa. La plataforma de IA examinó estos compuestos para evaluar su impacto previsto en la preservación muscular y la salud metabólica. YuvaBio ha entregado ahora a Northstrive una lista corta de candidatos de pequeñas moléculas para validación biológica y posible desarrollo clínico.
Northstrive Biosciences는 PMGC Holdings(나스닥: ELAB)의 자회사로서 Yuva Biosciences와 함께 인공지능 개발 프로그램의 2단계를 완료했습니다. 이번 협업은 YuvaBio의 독점 MitoNova™ AI 플랫폼을 활용해 비만 및 심대사 질환 치료 후보를 발굴합니다.
2단계 동안 YuvaBio는 비만, 심대사 장애 및 지질·포도당 대사에 중점을 둔 12개의 선별 라이브러리를 분석했습니다. AI 플랫폼은 이들 화합물이 근육 보존과 대사 건강에 미칠 것으로 예상되는 영향을 평가했습니다. YuvaBio는 현재 생물학적 검증 및 임상 개발 가능성을 위해 Northstrive에 소분자 후보 목록을 전달했습니다.
Northstrive Biosciences, filiale de PMGC Holdings (NASDAQ: ELAB), a achevé la phase II de son programme de développement IA avec Yuva Biosciences. Cette collaboration exploite la plateforme propriétaire MitoNova™ AI de YuvaBio pour identifier des traitements potentiels contre l'obésité et les maladies cardiométaboliques.
Pendant la phase II, YuvaBio a analysé 12 bibliothèques sélectionnées de composés axés sur l'obésité, les troubles cardiométaboliques et le métabolisme des lipides et du glucose. La plateforme IA a scruté ces composés pour évaluer leur impact prévu sur la préservation musculaire et la santé métabolique. YuvaBio a désormais remis à Northstrive une liste restreinte de candidats petites molécules pour validation biologique et développement clinique éventuel.
Northstrive Biosciences, eine Tochtergesellschaft von PMGC Holdings (NASDAQ: ELAB), hat Phase II seines KI-Entwicklungsprogramms mit Yuva Biosciences abgeschlossen. Die Zusammenarbeit nutzt YuvaBios proprietäre MitoNova™ AI-Plattform, um potenzielle Behandlungen für Adipositas und kardiometabolische Erkrankungen zu entdecken.
Während Phase II analysierte YuvaBio 12 kuratierte Bibliotheken von Verbindungen, die auf Adipositas, kardiometabolische Störungen sowie Lipid- und Glukosestoffwechsel ausgerichtet sind. Die KI-Plattform prüfte diese Verbindungen hinsichtlich ihres prognostizierten Einflusses auf Muskelerhalt und metabolische Gesundheit. YuvaBio hat Northstrive nun eine Shortlist kleiner Molekülkandidaten zur biologischen Validierung und möglichen klinischen Entwicklung übergeben.
- Strategic partnership leveraging advanced AI technology for drug discovery
- Successful completion of Phase II screening using proprietary MitoNova™ platform
- Access to 12 curated compound libraries targeting key disease areas
- Development pipeline focused on large market opportunities (obesity and cardiometabolic diseases)
- No compounds have been validated or tested yet
- Early-stage research with no guaranteed success in clinical development
Insights
Northstrive completes Phase II of AI drug discovery collaboration, receiving promising compound candidates for obesity and cardiometabolic diseases.
Northstrive Biosciences has reached a significant milestone in its artificial intelligence-driven drug discovery program, completing Phase II of its collaboration with Yuva Biosciences. This phase delivered concrete outputs in the form of a shortlist of small molecule candidates identified using YuvaBio's MitoNova™ AI platform, specifically targeting mitochondrial health mechanisms to address obesity and cardiometabolic conditions.
The strategic value of this collaboration lies in its targeted approach. YuvaBio compiled compounds from 12 curated libraries specifically designed around obesity, cardiometabolic disorders, and lipid & glucose metabolism. The AI platform then screened these libraries to evaluate compounds' predicted impact on a specific target involved in muscle preservation and metabolic health.
For investors, this represents a tangible progression in Northstrive's drug development pipeline. The company now faces a critical decision point as it reviews these AI-identified compounds to determine which warrant advancement to in vitro biological validation and potential clinical development. This marks the transition from computational discovery to experimental validation - a key value-creating step in pharmaceutical R&D.
The collaboration demonstrates how specialized AI platforms like MitoNova™ can accelerate the traditionally lengthy drug discovery process by narrowing focus to the most promising candidates. However, it's important to note that the compounds still require biological validation and face a lengthy development path before potentially reaching clinical trials.
- Northstrive Biosciences and Yuva Biosciences previously announced the AI Development Program, a collaboration leveraging MitoNova™, YuvaBio’s proprietary mitochondrial science-focused artificial intelligence platform, to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes and other cardiometabolic conditions.
- Phase II of this collaboration involved YuvaBio compiling a selection of small molecule candidates with the potential of promoting mitochondrial health to combat obesity and cardiac diseases.
NEWPORT BEACH, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced the completion of Phase II of the AI Development Program (“Phase II”) with strategic partner Yuva Biosciences, Inc. (“YuvaBio”). As part of the Phase II objective, YuvaBio delivered to Northstrive a shortlist of small molecule candidates YuvaBio believes has the potential to promote mitochondrial health to combat obesity and cardiac diseases.
YuvaBio completed Phase II by compiling a targeted collection of compounds drawn from 12 curated libraries. These libraries were designed to include molecules with activity across key disease areas—obesity, cardiometabolic disorders, and lipid & glucose metabolism—thereby aligning closely with Northstrive Bio’s therapeutic focus. MitoNova™, YuvaBio’s AI platform, screened the aggregated chemical space to evaluate predicted impact on a specified target involved in muscle preservation and metabolic health. YuvaBio presented Northstrive with a shortlist of compounds ready for biological validation in vitro. Northstrive has the opportunity to review the list of compounds and analyze their potential to be advanced to experimental testing and clinical development.
About Northstrive Biosciences Inc.
Northstrive Biosciences Inc., a PMGC Holdings Inc. company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Northstrive Biosciences’ lead asset, EL-22, leverages an engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.northstrivebio.com.
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC Holdings’ filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact:
IR@pmgcholdings.com
FAQ
What is the purpose of Northstrive Biosciences' collaboration with Yuva Biosciences?
What was achieved in Phase II of ELAB's AI Development Program?
How does YuvaBio's MitoNova™ platform contribute to ELAB's drug development process?
What are the next steps for Northstrive Biosciences after Phase II completion?
